NVO - Novo Nordisk A/S

NYSE - NYSE Delayed price. Currency in USD
48.72
-0.27 (-0.55%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous close48.99
Open48.38
Bid0.00 x 800
Ask0.00 x 4000
Day's range48.29 - 48.74
52-week range41.03 - 58.37
Volume868,886
Avg. volume1,463,964
Market cap116.118B
Beta0.82
PE ratio (TTM)19.20
EPS (TTM)2.54
Earnings dateN/A
Forward dividend & yield1.28 (2.61%)
Ex-dividend date2018-03-23
1y target est60.40
Trade prices are not sourced from all markets
  • Top Research Reports for Walmart, AT&T & Novo Nordisk
    Zacks2 days ago

    Top Research Reports for Walmart, AT&T & Novo Nordisk

    Top Research Reports for Walmart, AT&T & Novo Nordisk

  • AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates
    Market Realist5 days ago

    AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates

    AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products. Though it’s headquartered in London, England, the company reports its revenue in US dollars. The company is set to release its 1Q18 earnings on May 18.

  • Novo Nordisk Fights Payer Pressure With New Meds
    Motley Fool13 days ago

    Novo Nordisk Fights Payer Pressure With New Meds

    Sales of older medications are on the decline, but newer medications helped the revenue line grow at constant exchange rates.

  • Novo Nordisk (NVO) Q1 2018 Earnings Conference Call Transcript
    Motley Fool17 days ago

    Novo Nordisk (NVO) Q1 2018 Earnings Conference Call Transcript

    NVO earnings call for the period ending March 31, 2018.

  • NVS and NVO: Which Has Higher Upside Potential?
    Market Realist18 days ago

    NVS and NVO: Which Has Higher Upside Potential?

    Novartis’s (NVS) EV (enterprise value) is $206.9 billion and its EV-to-revenue ratio is 4.1. The stock is trading at a forward PE (price-to-earnings) ratio of 13.3, and its PEG (price-to-earnings-to-growth) ratio is 2.2. At present, Novartis’ price-to-sales ratio is 3.6, and its price-to-book ratio is 2.4.

  • These Pharma Stocks Offer the Most Upside Potential
    Market Realist18 days ago

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility. While the S&P 500 has recovered a bit from its fluctuation this year and has fallen only 0.12% year-to-date, the iShares US Pharmaceuticals ETF (IHE), SPDR S&P Pharmaceuticals ETF (XPH), VanEck Vectors Pharmaceutical ETF (PPH), and First Trust NASDAQ Pharmaceuticals ETF (FTXH) have fallen 4.4%, 5.9%, 3.5%, and 2.5%, respectively, indicating that pharma stocks are underperforming the overall market.

  • Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss
    Zacks18 days ago

    Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss

    Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.

  • Reuters18 days ago

    Drugmaker Novo Nordisk beats first quarter profit expectations, nudges up 2018 outlook

    Denmark's Novo Nordisk (NOVOb.CO), the world's biggest maker of diabetes drugs, reported first-quarter operating profit above expectations on Wednesday and raised the lower end of its 2018 sales and profit forecast. Operating profit fell 8 percent to 12.4 billion Danish crowns (1.5 billion pounds) in the January to March quarter compared with a year ago, hit by the depreciation of the U.S. dollar, but beat an average 11.8 billion crown forecast in a Reuters poll of analysts. With its traditional insulin treatments in the firing line due to U.S. price pressure, Novo Nordisk is pinning hopes for growth on new obesity drugs and a once-weekly injection and tablet version of its semaglutide drug.

  • GlaxoSmithKline’s 1Q18 Earnings: Consumer Healthcare Business
    Market Realist20 days ago

    GlaxoSmithKline’s 1Q18 Earnings: Consumer Healthcare Business

    GlaxoSmithKline’s (GSK) Consumer Healthcare business includes various products for oral health, wellness, nutrition, and skin health. The consumer healthcare business reported revenues of ~2.0 billion pounds in 1Q18, a ~3% decrease compared to 1Q17.

  • GlaxoSmithKline’s Pharmaceutical Business in 1Q18
    Market Realist20 days ago

    GlaxoSmithKline’s Pharmaceutical Business in 1Q18

    GlaxoSmithKline’s (GSK) Pharmaceuticals business includes various Immuno-inflammation products, HIV products, Respiratory products, and Established products. The Pharmaceuticals business segment reported revenues of ~4.0 billion pounds in 1Q18.

  • Analyst Recommendations for Novo Nordisk in April
    Market Realist23 days ago

    Analyst Recommendations for Novo Nordisk in April

    In March, Novo Nordisk (NVO) received an exclusive worldwide license for EpiDestiny’s sickle cell disease program, EPI01. Novo Nordisk will pay more than $400 million as an upfront payment to EpiDestiny for the license. EpiDestiny will also receive development and sales milestone payments from Novo Nordisk along with royalties on net sales of the product.

  • How Is Novo Nordisk Positioned before 1Q18?
    Market Realist23 days ago

    How Is Novo Nordisk Positioned before 1Q18?

    In 4Q17, Novo Nordisk (NVO) generated revenues of 28 billion Danish kroner, which is a ~2% decline on a YoY (year-over-year) basis.

  • Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018
    Market Realist24 days ago

    Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018

    In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY (year-over-year) growth in local currency.

  • Novo Nordisk’s Hemophilia Segment Could See Steady 2018 Growth
    Market Realist24 days ago

    Novo Nordisk’s Hemophilia Segment Could See Steady 2018 Growth

    In 4Q17, Novo Nordisk’s (NVO) hemophilia drugs NovoSeven and NovoEight generated revenues of 2.4 billion Danish kroner and 274 billion Danish kroner, respectively. That’s a ~3% and 1% YoY (year-over-year) growth in local currency.

  • Novo Nordisk’s Victoza Could See High Growth in 2018
    Market Realist24 days ago

    Novo Nordisk’s Victoza Could See High Growth in 2018

    In 4Q17, Novo Nordisk’s (NVO) Victoza generated revenues of 6.3 billion Danish kroner, which reflected a ~25% YoY (year-over-year) growth in local currency.

  • Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release
    Market Realist25 days ago

    Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release

    In 1Q18, analysts expect Sanofi’s (SNY) revenue to fall ~6.6% YoY (year-over-year) to 8.1 billion euros from 8.7 billion euros, and its earnings per share to fall to 1.13 euros from 1.42 euros. Sanofi’s stock price has fallen ~9.4% over the last 12 months and ~7.1% year-to-date. Analysts’ price target of $47.67 suggests the stock could return ~19.2% over the next 12 months based on its price of $39.95 on April 23.

  • A Review of Novo Nordisk’s Modern Insulin
    Market Realist25 days ago

    A Review of Novo Nordisk’s Modern Insulin

    Novo Nordisk’s (NVO) modern insulins include NovoRapid, Levemir, and NovoMix. In 4Q17, its modern insulins generated revenues of 10.4 billion Danish kroner, which is a ~9% YoY (year-over-year) decline in local currency.

  • Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?
    Market Realist25 days ago

    Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?

    Novo Nordisk’s (NVO) new-generation insulin portfolio consists of Tresiba, Xultophy, Ryzodeg, and Fiasp.

  • Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018
    Market Realist26 days ago

    Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018

    In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY (year-over-year) growth in local currency.

  • Ozempic Could Be Potential Driver for Novo Nordisk in 2018
    Market Realist26 days ago

    Ozempic Could Be Potential Driver for Novo Nordisk in 2018

    In December 2017, the FDA approved Novo Nordisk’s (NVO) Ozempic as an add-on to diet and exercise for the management of blood sugar levels in adult individuals with Type 2 diabetes.

  • Analysts’ Recommendations for Eli Lilly & Co. on April 20
    Market Realist27 days ago

    Analysts’ Recommendations for Eli Lilly & Co. on April 20

    Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 4Q17. The company reported EPS of $1.14 on revenues of ~$6.2 billion, compared to the estimated EPS of $1.07 on revenues of ~$5.9 billion. Analysts expect the company to report EPS of $1.14 on revenues of $5.5 billion during 1Q18.

  • Analysts’ Recommendations for Novartis on April 17
    Market Realistlast month

    Analysts’ Recommendations for Novartis on April 17

    Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.

  • Novartis’s 1Q18 Estimates: Expectations for Alcon
    Market Realistlast month

    Novartis’s 1Q18 Estimates: Expectations for Alcon

    Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. Alcon products are marketed in over 180 countries worldwide. Alcon is expected to report growth in revenue following increased demand for contact lenses and surgical products in 1Q18.

  • Novartis’s Innovative Medicines Segment in 1Q18
    Market Realistlast month

    Novartis’s Innovative Medicines Segment in 1Q18

    Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.

  • Novo Nordisk Stock Performance in 1Q18
    Market Realistlast month

    Novo Nordisk Stock Performance in 1Q18

    Novo Nordisk (NVO) is a global pharmaceutical company dealing with discovery, development, manufacturing, and commercialization of pharmaceutical products. The company has segregated its business into two segments: Diabetes & Obesity Care and Biopharmaceuticals.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes